Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-29
2005-03-29
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S474000
Reexamination Certificate
active
06872714
ABSTRACT:
The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that medicate a number of mammalian embryonic developmental processes.
REFERENCES:
patent: 5021409 (1991-06-01), Murrer et al.
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 20010033841 (2001-10-01), Luster et al.
patent: 20020039993 (2002-04-01), Winchester et al.
patent: 0 434 385 (1991-06-01), None
patent: 0 747 368 (1996-12-01), None
patent: WO 9216494 (1992-10-01), None
patent: WO 9312096 (1993-06-01), None
patent: WO 9518808 (1995-07-01), None
patent: WO 0002870 (2000-01-01), None
patent: WO 0045814 (2000-08-01), None
DeVries et al., On the Edge: the Physiological and Pathophysiological Role of Chemokines During Inflammatory and Immunological Responses, Seminars in Immunology, vol. 11, pp. 95-104, Apr. 1999.*
Hesselgesser et al., Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor, The Journal of Biological Chemistry, vol. 273, No. 25, pp. 15687-15692, Jun. 1998.*
International Search Report based on International Application No. PCT/CA99/00619.
Boshoff et al., “Angiogenic and HIV-Inhibitory Functions of KSHV-Encoded Chemokines”, SCIENCE, 278(5336):290-294 (1997).
Bridger et al., “Synthesis and Structure-Activity Relationships of Phenylenebis(methylene)-Linked Bis-Tetraazamacrocyles That Inhibit HIV Replication. Effects of Macrocyclic Ring Size and Substituents on the Aromatic Linker”, J. Med. Chem. 38:366-378 (1995).
Bridger et al., “Synthesis and Structure-Activity Relationships of Phenylenebis(methylene)-Linked Bis-Tetraazamacrocyles That Inhibit HIV Replication. 2. Effect of Heteroaromatic Linkers on the Activity of Bicyclams”, J. Med. Chem., 39(1):109-119 (1996).
Carroll et al. “Differential Regulation of HIV-1 Fusion Cofactor Expression by CD28 Costimulation of CD4+T Cells”, SCIENCE, 276(5310):273-276 (1997).
Chemical Abstracts, 113:40649 (1990).
Chemical Abstracts, 111:190197 (1987).
Chemical Abstracts, 123:56538 (1994).
De Clercq et al., “Highly Potent and Selective Inhibition of Human Immunodeficiency Virus by the Byclam Derivative JM3100”, Antimicrobial Agents & Chemotherapy, 38(4):668-674 (1994).
Fukuyama et al., “2- and 4-Nitrobenzenesulfonamides: Exceptionally Versatile Means for Preparation of Secondary Amines and Protection of Amines”, Tetrahedron Letters, 36(36):6373-74 (1995).
Gupta et al., “Chemokine Receptors in Human Endothelial Cells”, J. Biological Chem., 273(7):4282-87 (1998).
Hoxie et al., “CD4-Independent Infection by HIV-2 is Mediated by Fusin/CXCR4”, CELL, 87:745-756 (1996).
Joao et al. “Quantitative Structural Activity Relationship Study of Bis-Tetraazacyclic Compounds. A Novel Series of HIV-1 and HIV-2 Inhibitors”, J. Med. Chem. 38:3865-73 (1995).
Schols et al., “Inhibition of T-Tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4”, J. EXP. MED., 186(8):1383-88 (1997).
Schols et al., “Bycyclams, A Class of Potent Anti-HIV Agents, are Targeted at the HIV Coreceptor Fusin/CXCR-4”, Antiviral Research, 35:147-156 (1997).
Tachibana et al., “The Chemokine Receptor CXCR4 is Essential for Vascularization of the Gastrointestinal Tract”, NATURE, 393:591-94 (1998).
Wyatt et al., “The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens”, SCIENCE, 280:1884-88 (1998).
Zou et al., “Function of the Chemokine Receptor CXCR4 in Haematopoiesis and In Cerebellar Development”, NATURE, 393:595-99 (1998).
Bertolini et al., Cancer Research (2002) 62:3106-3112.
Bradstock et al., Leukemia (2000) 14:882-888.
Burger et al., Blood (2000) 96(8):2655-2663.
Burger et al., Blood (1999) 94(11):3658-3667.
De Bont et al., Cancer Research (2001) 61:7654-7659.
Dürig et al., Leukemia (2001) 15:752-756.
Gazitt and Liu, Stem Cells (2001) 19:37-45.
Geminder et al., The Journal of Immunology (2001) 167:4747-4757.
Hatse et al., CXC-chemokine receptor 4 as a potential new therapeutic target for neuroblastoma and breast cancer, Abstract No.: P 669, 2002.
Koshiba et al., Clinical Cancer Research (2000) 6:3530-3535.
Lagneaux et al., Poster Session: Bone Marrow Stroma and Marrow Failure, Saturday, Jul. 6, 2002, Abstract #72.
Libura et al., Blood (2002) 100(7):2597-2606.
Möhle et al., Blood (1998) 91(12):4523-4530.
Moore et al., Journal of Investigative Medicine (1998) 46(4):113-120.
Müller et al., (2001) 410:50-56.
Rempel et al., Clinical Cancer Research (2000) 6:102-111.
Robledo et al., The Journal of Biological Chemistry (2001) 276(48):45098-45105.
Sanz-Rodriguez et al., Blood (2001) 97(2):346-351.
Scotton et al., Cancer Research (2001) 61:4961-4965.
Shen et al., Experimental Hematology (2001) 29:1439-1447.
AnorMed Inc.
Coleman Brenda
Morrison & Foerster / LLP
LandOfFree
Methods to modulate conditions mediated by the CXCR4 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to modulate conditions mediated by the CXCR4 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to modulate conditions mediated by the CXCR4 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403420